期刊
JOURNAL OF VIROLOGY
卷 95, 期 23, 页码 -出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/JVI.01313-21
关键词
COVID-19; SARS-CoV-2 variants of concern; mRNA-1273; neutralization
类别
资金
- Moderna, Inc.
- Biomedical Advanced Research and Development Authority, Department of Health and Human Services [75A50120C00034]
- National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD
- NIAID [UM1AI148373, UM1AI148576, UM1AI148684]
- NIH [P51 OD011132]
- NIH AID [AI149644, HHSN272201500002C]
- [NCT04283461]
The study demonstrates that vaccination with the mRNA-1273 COVID-19 vaccine produces neutralizing antibodies against various emerging variants, including variants of concern and interest. While neutralization of some variants may be reduced compared to the wild-type virus, the protective effect is still present, informing vaccination strategies against COVID-19.
The emergence of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) variants has led to growing concerns over increased transmissibility and the ability of some variants to partially escape immunity. Sera from participants immunized on a prime-boost schedule with the mRNA-1273 COVID-19 vaccine were tested for neutralizing activity against several SARS-CoV-2 variants, including variants of concern (VOCs) and variants of interest (VOIs), compared to neutralization of the wild-type SARS-CoV-2 virus (designated D614G). Results showed minimal, statistically nonsignificant effects on neutralization titers against the B.1.1.7 (Alpha) variant (1.2-fold reduction compared with D614G); other VOCs, such as B.1.351 (Beta, including B.1.351-v1, B.1.351-v2, and B.1.351 v3), P.1 (Gamma), and B.1.617.2 (Delta), showed significantly decreased neutralization titers ranging from 2.1-fold to 8.4-fold reductions compared with D614G, although all remained susceptible to mRNA-1273-elicited serum neutralization. IMPORTANCE In light of multiple variants of SARS-CoV-2 that have been documented globally during the COVID-19 pandemic, it remains important to continually assess the ability of currently available vaccines to confer protection against newly emerging variants. Data presented herein indicate that immunization with the mRNA-1273 COVID-19 vaccine produces neutralizing antibodies against key emerging variants tested, including variants of concern and variants of interest. While the serum neutralization elicited by mRNA-1273 against most variants tested was reduced compared with that against the wild-type virus, the level of neutralization is still expected to be protective. Such data are crucial to inform ongoing and future vaccination strategies to combat COVID-19.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据